Mr. Rene Goehrum reports

BIOSYENT ANNOUNCES APPROVAL OF NEW PRODUCT

BioSyent Inc.'s subsidiary, BioSyent Pharma Inc., has received regulatory approval from Health Canada for a new oncology supportive care product. BioSyent Pharma signed an exclusive Canadian distribution agreement for this product with a European partner in December, 2022.

"We are pleased to have received marketing approval for this new product, bringing it one step closer to launch in Canada," said Rene Goehrum, president and chief executive officer of BioSyent. "We look forward to entering the oncology supportive care therapeutic area with this new product, which enhances our specialty product portfolio and contributes to our ongoing growth."

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other health care products that have been developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the company has 12,087,519 common shares outstanding.

We seek Safe Harbor.